372 related articles for article (PubMed ID: 12673735)
21. Downregulation of retinal GLUT1 in diabetes by ubiquitinylation.
Fernandes R; Carvalho AL; Kumagai A; Seica R; Hosoya K; Terasaki T; Murta J; Pereira P; Faro C
Mol Vis; 2004 Aug; 10():618-28. PubMed ID: 15359219
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic significance of overexpression of Golgi membrane protein 1 in prostate cancer.
Li W; Wang X; Li B; Lu J; Chen G
Urology; 2012 Oct; 80(4):952.e1-7. PubMed ID: 22840862
[TBL] [Abstract][Full Text] [Related]
23. mRNA expression of the five membrane-type matrix metalloproteinases MT1-MT5 in human prostatic cell lines and their down-regulation in human malignant prostatic tissue.
Jung M; Römer A; Keyszer G; Lein M; Kristiansen G; Schnorr D; Loening SA; Jung K
Prostate; 2003 May; 55(2):89-98. PubMed ID: 12661033
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
[TBL] [Abstract][Full Text] [Related]
25. Gene expression of glucose transporters and its regulation by glucose in mesothelial cells.
Lu C; Ye R; Yang Q; Yang X; Li H; Li Y
Chin Med J (Engl); 2001 May; 114(5):477-80. PubMed ID: 11780407
[TBL] [Abstract][Full Text] [Related]
26. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues.
Godoy A; Ulloa V; Rodríguez F; Reinicke K; Yañez AJ; García Mde L; Medina RA; Carrasco M; Barberis S; Castro T; Martínez F; Koch X; Vera JC; Poblete MT; Figueroa CD; Peruzzo B; Pérez F; Nualart F
J Cell Physiol; 2006 Jun; 207(3):614-27. PubMed ID: 16523487
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
28. In vitro and ex vivo expression of nucleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate.
Bocker T; Bittinger A; Wieland W; Buettner R; Fauser G; Hofstaedter F; Rüschoff J
Mod Pathol; 1995 Apr; 8(3):226-31. PubMed ID: 7542384
[TBL] [Abstract][Full Text] [Related]
29. Identification of the facilitative glucose transporter 12 gene Glut12 in mouse preimplantation embryos.
Zhou Y; Kaye PL; Pantaleon M
Gene Expr Patterns; 2004 Oct; 4(6):621-31. PubMed ID: 15465484
[TBL] [Abstract][Full Text] [Related]
30. Beta-human chorionic gonadotropin in semen: a marker for early detection of prostate cancer?
Daja MM; Aghmesheh M; Ow KT; Rohde PR; Barrow KD; Russell PJ
Mol Urol; 2000; 4(4):421-7. PubMed ID: 11156711
[TBL] [Abstract][Full Text] [Related]
31. Identification and function of glucose transporter 1 in human mesangial cells.
Li Y; Liu Z; Liu D; Zhang J; Chen Z; Li L
Chin Med J (Engl); 2001 Aug; 114(8):824-8. PubMed ID: 11780359
[TBL] [Abstract][Full Text] [Related]
32. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue.
Hamdy FC; Autzen P; Robinson MC; Horne CH; Neal DE; Robson CN
Cancer Res; 1997 Oct; 57(19):4427-31. PubMed ID: 9331107
[TBL] [Abstract][Full Text] [Related]
33. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304
[TBL] [Abstract][Full Text] [Related]
34. Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer.
Ruiz M; Troncoso P; Bruns C; Bar-Eli M
Clin Cancer Res; 2001 Dec; 7(12):4086-95. PubMed ID: 11751506
[TBL] [Abstract][Full Text] [Related]
35. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
Cindolo L; Franco R; Cantile M; Schiavo G; Liguori G; Chiodini P; Salzano L; Autorino R; Di Blasi A; Falsaperla M; Feudale E; Botti G; Gallo A; Cillo C
Eur Urol; 2007 Nov; 52(5):1365-73. PubMed ID: 17126478
[TBL] [Abstract][Full Text] [Related]
36. Expression of facilitative glucose transporters in gastric tumors.
Noguchi Y; Marat D; Saito A; Yoshikawa T; Doi C; Fukuzawa K; Tsuburaya A; Satoh S; Ito T
Hepatogastroenterology; 1999; 46(28):2683-9. PubMed ID: 10522065
[TBL] [Abstract][Full Text] [Related]
37. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
Rehman I; Azzouzi AR; Cross SS; Deloulme JC; Catto JW; Wylde N; Larre S; Champigneuille J; Hamdy FC
Hum Pathol; 2004 Nov; 35(11):1385-91. PubMed ID: 15668896
[TBL] [Abstract][Full Text] [Related]
38. GLUT1 glucose transporter: a highly sensitive marker of malignancy in body cavity effusions.
Burstein DE; Reder I; Weiser K; Tong T; Pritsker A; Haber RS
Mod Pathol; 1998 Apr; 11(4):392-6. PubMed ID: 9578091
[TBL] [Abstract][Full Text] [Related]
39. Glucose transporter plasticity during memory processing.
Choeiri C; Staines W; Miki T; Seino S; Messier C
Neuroscience; 2005; 130(3):591-600. PubMed ID: 15590143
[TBL] [Abstract][Full Text] [Related]
40. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.
Mariani S; Salvatori L; Basciani S; Arizzi M; Franco G; Petrangeli E; Spera G; Gnessi L
J Urol; 2006 Jun; 175(6):2072-7; discussion 2077. PubMed ID: 16697805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
